Rep. Marjorie Taylor Greene Buys Merck & Co., Inc. (NYSE:MRK) Shares

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Merck & Co., Inc. (NYSE:MRK). In a filing disclosed on May 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in Merck & Co., Inc. stock on May 5th. The trade occurred in the Representative’s “MARJORIE IRA” account.

Representative Marjorie Taylor Greene also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of AbbVie (NYSE:ABBV) on 5/5/2025.
• Purchased $1,001 – $15,000 in shares of Occidental Petroleum (NYSE:OXY) on 5/5/2025.
• Purchased $1,001 – $15,000 in shares of Paychex (NASDAQ:PAYX) on 5/5/2025.
• Purchased $1,001 – $15,000 in shares of MercadoLibre (NASDAQ:MELI) on 5/5/2025.
• Purchased $1,001 – $15,000 in shares of Starbucks (NASDAQ:SBUX) on 5/5/2025.
• Purchased $1,001 – $15,000 in shares of BP (NYSE:BP) on 5/5/2025.
• Purchased $1,001 – $15,000 in shares of Gilead Sciences (NASDAQ:GILD) on 5/5/2025.
• Purchased $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 5/5/2025.
• Purchased $1,001 – $15,000 in shares of Advanced Micro Devices (NASDAQ:AMD) on 5/5/2025.
• Purchased $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOG) on 5/5/2025.

Merck & Co., Inc. Stock Up 0.1 %

MRK stock opened at $79.09 on Thursday. The company’s 50 day moving average is $85.91 and its two-hundred day moving average is $93.72. The company has a current ratio of 1.36, a quick ratio of 1.15 and a debt-to-equity ratio of 0.79. Merck & Co., Inc. has a twelve month low of $75.93 and a twelve month high of $134.63. The stock has a market cap of $199.45 billion, a P/E ratio of 11.75, a PEG ratio of 0.77 and a beta of 0.43.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, April 24th. The company reported $2.22 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.06. Merck & Co., Inc. had a return on equity of 45.35% and a net margin of 26.67%. The firm had revenue of $15.53 billion during the quarter, compared to the consensus estimate of $15.59 billion. During the same period last year, the company earned $2.07 earnings per share. The company’s revenue for the quarter was down 1.6% on a year-over-year basis. Research analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. declared that its Board of Directors has initiated a share buyback plan on Tuesday, January 28th that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the company to repurchase up to 4.1% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s leadership believes its stock is undervalued.

Institutional Investors Weigh In On Merck & Co., Inc.

A number of hedge funds have recently added to or reduced their stakes in MRK. Principal Financial Group Inc. lifted its holdings in Merck & Co., Inc. by 8.9% in the third quarter. Principal Financial Group Inc. now owns 6,355,950 shares of the company’s stock worth $721,782,000 after purchasing an additional 518,270 shares during the period. Nordea Investment Management AB raised its position in Merck & Co., Inc. by 4.7% in the fourth quarter. Nordea Investment Management AB now owns 9,399,643 shares of the company’s stock worth $933,761,000 after acquiring an additional 422,382 shares in the last quarter. Pensionfund Sabic boosted its position in shares of Merck & Co., Inc. by 58.5% during the 4th quarter. Pensionfund Sabic now owns 32,500 shares of the company’s stock valued at $3,233,000 after purchasing an additional 12,000 shares in the last quarter. Neville Rodie & Shaw Inc. grew its stake in shares of Merck & Co., Inc. by 0.8% in the 4th quarter. Neville Rodie & Shaw Inc. now owns 177,365 shares of the company’s stock worth $17,644,000 after purchasing an additional 1,382 shares during the last quarter. Finally, Doliver Advisors LP grew its stake in shares of Merck & Co., Inc. by 24.9% in the 4th quarter. Doliver Advisors LP now owns 16,347 shares of the company’s stock worth $1,626,000 after purchasing an additional 3,260 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Merck & Co., Inc.

In other news, SVP Dalton E. Smart III sold 4,262 shares of the business’s stock in a transaction that occurred on Friday, April 25th. The shares were sold at an average price of $82.76, for a total transaction of $352,723.12. Following the sale, the senior vice president now owns 7,778 shares in the company, valued at $643,707.28. The trade was a 35.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.09% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on MRK shares. Leerink Partners decreased their target price on shares of Merck & Co., Inc. from $136.00 to $119.00 and set an “outperform” rating on the stock in a research report on Monday, January 13th. Cantor Fitzgerald assumed coverage on shares of Merck & Co., Inc. in a research note on Tuesday, April 22nd. They set a “neutral” rating and a $85.00 price target on the stock. Truist Financial reiterated a “hold” rating and issued a $110.00 price target (down from $130.00) on shares of Merck & Co., Inc. in a report on Wednesday, January 8th. Citigroup lowered their target price on Merck & Co., Inc. from $125.00 to $115.00 and set a “buy” rating for the company in a research note on Wednesday, February 5th. Finally, Morgan Stanley decreased their price target on shares of Merck & Co., Inc. from $113.00 to $106.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 5th. Twelve equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and an average target price of $111.13.

About Representative Greene

Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia’s 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia’s 14th Congressional District. She declared candidacy for the 2026 election.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.